9,398 Shares in Moderna, Inc. (NASDAQ:MRNA) Purchased by Kentucky Retirement Systems Insurance Trust Fund

Kentucky Retirement Systems Insurance Trust Fund purchased a new position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 9,398 shares of the company's stock, valued at approximately $266,000.

Other institutional investors have also recently made changes to their positions in the company. Sentry Investment Management LLC bought a new position in shares of Moderna in the 1st quarter worth $31,000. Venturi Wealth Management LLC raised its holdings in Moderna by 286.2% in the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock worth $37,000 after purchasing an additional 664 shares in the last quarter. Crowley Wealth Management Inc. bought a new position in Moderna in the fourth quarter worth about $41,000. Itau Unibanco Holding S.A. lifted its position in shares of Moderna by 51.2% during the fourth quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock valued at $42,000 after buying an additional 343 shares during the last quarter. Finally, Vega Investment Solutions bought a new stake in shares of Moderna in the 4th quarter valued at about $45,000. Hedge funds and other institutional investors own 75.33% of the company's stock.

Moderna Stock Performance

Shares of Moderna stock traded up $0.68 on Thursday, hitting $27.54. The company's stock had a trading volume of 9,257,022 shares, compared to its average volume of 8,531,673. The company has a market capitalization of $10.65 billion, a price-to-earnings ratio of -3.15 and a beta of 1.86. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $135.37. The firm has a fifty day moving average price of $26.30 and a 200-day moving average price of $32.10.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, beating the consensus estimate of ($2.92) by $0.40. The company had revenue of $108.00 million for the quarter, compared to analyst estimates of $130.35 million. Moderna had a negative return on equity of 28.69% and a negative net margin of 105.67%. Moderna's quarterly revenue was down 35.3% compared to the same quarter last year. During the same period last year, the company earned ($3.07) earnings per share. As a group, analysts forecast that Moderna, Inc. will post -9.61 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently commented on MRNA. Morgan Stanley decreased their target price on shares of Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a research report on Wednesday, April 9th. JPMorgan Chase & Co. lowered their price objective on Moderna from $33.00 to $26.00 and set an "underweight" rating for the company in a research report on Thursday, May 22nd. Evercore ISI reduced their target price on Moderna from $50.00 to $32.00 and set an "in-line" rating on the stock in a research report on Friday, May 2nd. Barclays decreased their price target on Moderna from $45.00 to $40.00 and set an "equal weight" rating for the company in a research note on Friday, May 2nd. Finally, Citigroup assumed coverage on shares of Moderna in a research report on Thursday, March 13th. They set a "neutral" rating and a $40.00 target price on the stock. Four research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $46.61.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.